|1.||Gnant, Michael: 7 articles (09/2012 - 12/2002)|
|2.||Mlineritsch, Brigitte: 6 articles (07/2011 - 12/2002)|
|3.||Jakesz, Raimund: 6 articles (07/2011 - 12/2002)|
|4.||Dubsky, Peter: 5 articles (09/2012 - 09/2008)|
|5.||von Minckwitz, Gunter: 5 articles (10/2011 - 08/2005)|
|6.||Menzel, Christian: 5 articles (07/2011 - 12/2002)|
|7.||Seifert, Michael: 5 articles (07/2011 - 12/2002)|
|8.||Samonigg, Hellmut: 5 articles (07/2011 - 12/2002)|
|9.||Bae, Kyounghwa: 5 articles (05/2009 - 12/2007)|
|10.||Shipley, William U: 5 articles (01/2009 - 12/2002)|
|1.||Breast Neoplasms (Breast Cancer)
04/01/1995 - "A case report is presented of a patient with premenopausal recurrent breast cancer in whom good results were obtained by concomitant administration of Zoladex and CPA."
05/01/2006 - "These data show that the addition of goserelin to standard adjuvant therapy is more effective than standard therapy alone in pre-menopausal women with early breast cancer."
10/01/2011 - "For pre/perimenopausal women with lymph-node-negative ER-positive breast cancer, CMF followed by goserelin improved DFS in comparison with either modality alone. "
06/10/2011 - "We aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer. "
10/01/2009 - "A total of 285 premenopausal breast cancer patients, in a randomized adjuvant trial (Zoladex in premenopausal patients (ZIPP)), were assigned to a study on ovarian function. "
|2.||Prostatic Neoplasms (Prostate Cancer)
08/01/2005 - "RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin."
01/01/1995 - "A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. "
11/01/1988 - "The results indicated that Zoladex in a once monthly regimen may be of great advantage to elderly patients with prostatic cancer, and allow an improved patient compliance: Zoladex may not only produce clinical remission but also improve the quality of life."
06/01/2011 - "Fourty-seven patients with prostate cancer receiving hormonal manipulation by goserelin acetate were enrolled in this study. "
10/01/2008 - "We assessed the relationship between duration of GnRHa therapy and cardiovascular mortality in a large randomized trial of men treated with short-term versus longer-term adjuvant goserelin and radiation therapy (RT) for locally advanced prostate cancer. "
06/01/1998 - "Goserelin plus HRT is as effective as goserelin alone in relieving pelvic symptoms of endometriosis and attenuates both the loss of BMD and the physiologic side effects of hot flushes and vaginal dryness associated with goserelin therapy."
06/01/1992 - "Zoladex depot therapy proved to be safe and effective in the medical treatment of endometriosis."
08/01/2012 - "To evaluate the short-term and long-term efficacy of conservative laparoscopic surgery combine with goserelin in treatment of severe ovarian endometriosis. "
08/01/2012 - "[Efficacy of conservative laparoscopic surgery combined with goserelin in treatment of 206 patients with severe ovarian endometriosis at short-term and long-term follow-up]."
08/01/2015 - "Reduced endometrial staining of LIF, LIFR and gp130, unaffected by surgery and goserelin, was seen in endometriosis patients without a recorded pregnancy during the study. "
01/01/1990 - "Although there were no significant differences in the overall subjective response to both treatments, a faster improvement, with respect to pain and performance status was noted in the Zoladex plus CPA group (8 weeks) compared to Zoladex alone (12 weeks). "
01/01/2014 - "Fifteen-second skin icing using a frozen gel pack is effective for reducing goserelin injection pain."
10/01/2010 - "Icing at the injection site of goserelin acetate is a safe and effective method to reduce injection pain. "
01/01/2014 - "The efficacy of skin icing to reduce the pain of goserelin injection has been reported. "
01/01/2014 - "For 55 consecutive patients who received goserelin (10.8 mg) injection, pain was evaluated employing a visual analog scale (VAS). "
02/01/2010 - "The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of goserelin was limited to patients whose tumors showed PVI. "
10/01/2011 - "Patients with ER-negative tumors whose treatment included CMF had similar DFS (12-year DFS CMF = 67%; 12-year DFS CMF→ goserelin = 69%) compared with goserelin alone (12-year DFS = 61%, P= NS). "
12/17/2003 - "Patients with ER-negative tumors achieved better disease-free survival if they received CMF (5-year DFS for CMF = 84%, 95% confidence interval [CI] = 77% to 91%; 5-year DFS for CMF --> goserelin = 88%, 95% CI = 82% to 94%) than if they received goserelin alone (5-year DFS = 73%, 95% CI = 64% to 81%). "
03/01/1997 - "However, in patients with centrally reviewed tumors with a Gleason score of 8 to 10, the difference in actuarial 5-year survival (66% on the adjuvant goserelin arm v 55% on the observation arm) reaches statistical significance (P = .03). "
01/01/1989 - "A steering group has devised a protocol to compare relapse-free survival rates between women under 50 with stage II cancer, given CMF or Zoladex as adjuvant therapy. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|8.||acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide
|1.||Drug Therapy (Chemotherapy)